CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Chief Executive Officer bought 21,000 shares at $2.50 ($52,500)
- 4 Open-market buy Director bought 10,000 shares at $3.04 ($30,400)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Director acquired 16,000 shares (option exercise)
- 4 Shares withheld for taxes Chief Executive Officer gave up 169,439 shares (to pay taxes)
- 4 Open-market buy Director bought 10,000 shares at $3.08 ($30,800)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $3.16 ($15,800)
- 4 Open-market buy Director bought 5,000 shares at $3.39 ($16,950)
- 4 Open-market buy Director bought 10,000 shares at $3.14 ($31,400)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $3.15 ($15,750)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $2.85 ($28,500)
- 4 Open-market buy Director bought 5,000 shares at $2.82 ($14,100)
- 4 Open-market buy Director bought 3,000 shares at an average $2.94 ($8,820)
- 4 Open-market buy Director bought 2,000 shares at $3.01 ($6,020)
- 4 Open-market buy Director bought 6,000 shares at $2.59 ($15,540)
- 4 Open-market buy Director bought 10,000 shares at $2.57 ($25,700)
Page 2 of 24 · 471 filings